HN2012001160A - Agonistas mglu2 - Google Patents

Agonistas mglu2

Info

Publication number
HN2012001160A
HN2012001160A HN2012001160A HN2012001160A HN2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A HN 2012001160 A HN2012001160 A HN 2012001160A
Authority
HN
Honduras
Prior art keywords
mglu2
mglu2 agonists
agonists
aguists
schizophrenia
Prior art date
Application number
HN2012001160A
Other languages
English (en)
Spanish (es)
Inventor
Monn James Allen
Taboada Martinez Lorena
Shaw Bruce William
Prieto Lourdes
Montero Salgado Carlos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2012001160(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2012001160A publication Critical patent/HN2012001160A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HN2012001160A 2009-12-21 2012-05-30 Agonistas mglu2 HN2012001160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17

Publications (1)

Publication Number Publication Date
HN2012001160A true HN2012001160A (es) 2015-08-24

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2012001160A HN2012001160A (es) 2009-12-21 2012-05-30 Agonistas mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (enExample)
EP (1) EP2516406B1 (enExample)
JP (1) JP5779190B2 (enExample)
KR (1) KR101395356B1 (enExample)
CN (1) CN102695701B (enExample)
AR (1) AR079343A1 (enExample)
AU (1) AU2010340039B2 (enExample)
BR (1) BR112012017188B1 (enExample)
CA (1) CA2784667C (enExample)
CR (1) CR20120322A (enExample)
CY (1) CY1114880T1 (enExample)
DK (1) DK2516406T3 (enExample)
DO (1) DOP2012000173A (enExample)
EA (1) EA020229B1 (enExample)
EC (1) ECSP12011989A (enExample)
ES (1) ES2435651T3 (enExample)
HN (1) HN2012001160A (enExample)
HR (1) HRP20131052T1 (enExample)
IL (1) IL220011A (enExample)
JO (1) JO2978B1 (enExample)
MA (1) MA33824B1 (enExample)
MX (1) MX2012007332A (enExample)
MY (1) MY160618A (enExample)
NZ (1) NZ600305A (enExample)
PE (1) PE20121688A1 (enExample)
PH (1) PH12012501253A1 (enExample)
PL (1) PL2516406T3 (enExample)
PT (1) PT2516406E (enExample)
RS (1) RS53063B (enExample)
SG (1) SG181836A1 (enExample)
SI (1) SI2516406T1 (enExample)
TN (1) TN2012000281A1 (enExample)
TW (1) TWI477490B (enExample)
UA (1) UA107684C2 (enExample)
WO (1) WO2011084437A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2790284C (en) 2010-02-17 2019-01-08 Takeda Pharmaceutical Company Limited Thieno-pyrimidine compounds having cdc7 inhibitory activity
WO2012068041A1 (en) * 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
BR112013031928B1 (pt) * 2011-06-17 2022-05-24 Eli Lilly And Company Derivados de ácido biciclo (3.1.0) hexano-2,6-dicarboxílico, seu uso, e composição farmacêutica
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
PL3277270T3 (pl) 2015-04-01 2022-02-14 Akebia Therapeutics, Inc. Kompozycje i sposoby leczenia niedokrwistości

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
EP1370519A1 (en) * 2001-02-22 2003-12-17 Eli Lilly And Company Synthetic excitatory amino acids
DK1517915T3 (da) 2002-06-11 2009-03-16 Lilly Co Eli Promedikamenter af excitatoriske aminosyrer
WO2005000790A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. 2-アミノビシクロ[3.1.0]ヘキサン-2,6-ジカルボン酸誘導体
WO2012068041A1 (en) * 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物

Also Published As

Publication number Publication date
EA201290558A1 (ru) 2012-12-28
CA2784667A1 (en) 2011-07-14
NZ600305A (en) 2014-01-31
HRP20131052T1 (hr) 2013-12-06
PH12012501253A1 (en) 2014-08-01
BR112012017188A8 (pt) 2016-10-04
BR112012017188A2 (pt) 2016-03-22
PE20121688A1 (es) 2012-12-05
IL220011A0 (en) 2012-07-31
US20110152334A1 (en) 2011-06-23
EP2516406B1 (en) 2013-09-18
HK1171228A1 (en) 2013-03-22
PL2516406T3 (pl) 2014-03-31
BR112012017188B1 (pt) 2021-06-22
EP2516406A1 (en) 2012-10-31
IL220011A (en) 2014-03-31
EA020229B1 (ru) 2014-09-30
KR20120094056A (ko) 2012-08-23
JO2978B1 (en) 2016-03-15
AU2010340039A1 (en) 2012-08-09
TN2012000281A1 (en) 2013-12-12
CY1114880T1 (el) 2016-12-14
CN102695701A (zh) 2012-09-26
MA33824B1 (fr) 2012-12-03
SI2516406T1 (sl) 2013-11-29
RS53063B (sr) 2014-04-30
CR20120322A (es) 2012-07-10
AR079343A1 (es) 2012-01-18
UA107684C2 (xx) 2015-02-10
TWI477490B (zh) 2015-03-21
JP2013514974A (ja) 2013-05-02
KR101395356B1 (ko) 2014-05-14
US8318184B2 (en) 2012-11-27
ES2435651T3 (es) 2013-12-20
ECSP12011989A (es) 2012-07-31
MY160618A (en) 2017-03-15
CA2784667C (en) 2014-11-18
MX2012007332A (es) 2012-07-20
PT2516406E (pt) 2013-10-10
DOP2012000173A (es) 2012-11-30
SG181836A1 (en) 2012-08-30
WO2011084437A1 (en) 2011-07-14
CN102695701B (zh) 2014-10-01
AU2010340039B2 (en) 2014-03-20
JP5779190B2 (ja) 2015-09-16
DK2516406T3 (da) 2013-10-14
TW201144290A (en) 2011-12-16

Similar Documents

Publication Publication Date Title
ECSP12011989A (es) Agonistas de mglu2
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CO6612235A2 (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
ECSP11011541A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
UY34342A (es) ?derivados de pirrolopirimidina y purina?.
CR11202S (es) Botella
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
UY33504A (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
UY34167A (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CR20110202A (es) Antagonistas de la via hedgehog de ftalazina disustituida
HN2010001614A (es) Confitura
MX2015003909A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
CL2009001363S1 (es) Pieza para maquina de afeitar.
CR20110550S (es) Botella
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
HN2009003469A (es) Biscocho lleno
HN2011002059A (es) Tinturas azoicas fibrorreactivas , su preparacion y su uso
EA201391700A1 (ru) АГОНИСТЫ РЕЦЕПТОРА mGlu2
CL2011002880S1 (es) Rodamiento de bola
CL2009001553S1 (es) Mesa.
CL2009001552S1 (es) Mesa.
CL2009000054S1 (es) Frasco para cosmeticos.
CL2009000055S1 (es) Frasco para cosmeticos.
CR20110546S (es) Es diseno ornamental de la botella tal y como se muestra y describe en la presente solicitud.